A remarkable new scientific discovery is offering unprecedented hope for those affected by Multiple Sclerosis. Researchers have developed a modified HIV drug called Kamuvudine-9 that shows incredible potential not just in stopping the disease, but in actively reversing its devastating effects. In Multiple Sclerosis, the body's immune system mistakenly attacks the protective coating around nerve fibers, leading to severe symptoms like vision loss and paralysis. The newly engineered drug works by calming the specific inflammatory response that drives this nerve damage. During recent laboratory trials, Kamuvudine-9 successfully halted the destruction of nerve insulation and significantly lowered key markers of nerve damage in the bloodstream. Most importantly, the treatment actively reversed preexisting paralysis and restored lost vision in animal models. The path to human treatment looks exceptionally promising. Existing patient data already reveals that individuals taking similar antiviral medications for other conditions have a much lower risk of developing MS and experience fewer disease relapses. By safely targeting the root cause of nerve inflammation, this breakthrough paves a clear and exciting path toward human clinical trials and a potential new era of recovery for patients worldwide. Study paper: Praveen Yerramothu et al, The nucleoside analog kamuvudine-9 shows protective and therapeutic efficacy in a mouse model of multiple sclerosis, Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.aei2870.